Semin Respir Crit Care Med 2011; 32(6): 754-763
DOI: 10.1055/s-0031-1295723
© Thieme Medical Publishers

Pulmonary Coccidioidomycosis

George R. Thompson1 , 2  III 
  • 1Department of Internal Medicine, Division of Infectious Diseases, University of California–Davis, Davis, California
  • 2Department of Medical Microbiology and Immunology, University of California–Davis, Davis, California
Further Information

Publication History

Publication Date:
13 December 2011 (online)

ABSTRACT

Coccidioidomycosis refers to the spectrum of disease caused by the dimorphic fungi Coccidioides immitis and Coccidioides posadasii. Clinical manifestations vary depending upon both the extent of infection and the immune status of the host. Coccidioidomycosis has been reported to involve almost all organ systems; however, pulmonary disease is the most common clinical manifestation. The incidence of coccidioidomycosis continues to rise, and primary coccidioidal pneumonia accounts for 17 to 29% of all cases of community-acquired pneumonia in endemic regions. The majority of patients with coccidioidomycosis resolve their initial infection without sequelae; however, several patients develop complications of disease ranging in severity from complicated pulmonary coccidioidomycosis to widely disseminated disease with immediately life-threatening manifestations. This review focuses on complications of pulmonary coccidioidomycosis with an emphasis on the management of primary coccidioidal infection, solitary pulmonary nodules, pleural effusions, cavitary disease, acute respiratory distress syndrome (ARDS), miliary disease, and sepsis.

REFERENCES

  • 1 Hirschmann J V. The early history of coccidioidomycosis: 1892–1945.  Clin Infect Dis. 2007;  44 (9) 1202-1207
  • 2 Kolivras K N, Comrie A C. Modeling valley fever (coccidioidomycosis) incidence on the basis of climate conditions.  Int J Biometeorol. 2003;  47 (2) 87-101
  • 3 Sunenshine R H, Anderson S, Erhart L et al.. Public health surveillance for coccidioidomycosis in Arizona.  Ann N Y Acad Sci. 2007;  1111 96-102
  • 4 Centers for Disease Control and Prevention (CDC) . Increase in Coccidioidomycosis-California, 2000–2007.  MMWR Morb Mortal Wkly Rep. 2009;  58 (5) 105-109
  • 5 Werner S B, Pappagianis D, Heindl I, Mickel A. An epidemic of coccidioidomycosis among archeology students in northern California.  N Engl J Med. 1972;  286 (10) 507-512
  • 6 From the Centers for Disease Control and Prevention. Coccidioidomycosis in workers at an archeologic site–Dinosaur National Monument, Utah, June-July 2001.  JAMA. 2001;  286 (24) 3072-3073
  • 7 Petersen L R, Marshall S L, Barton-Dickson C et al.. Coccidioidomycosis among workers at an archeological site, northeastern Utah.  Emerg Infect Dis. 2004;  10 (4) 637-642
  • 8 Bergstrom L, Yocum D E, Ampel N M et al.. Increased risk of coccidioidomycosis in patients treated with tumor necrosis factor alpha antagonists.  Arthritis Rheum. 2004;  50 (6) 1959-1966
  • 9 Blair J E, Logan J L. Coccidioidomycosis in solid organ transplantation.  Clin Infect Dis. 2001;  33 (9) 1536-1544
  • 10 Glenn T J, Blair J E, Adams R H. Coccidioidomycosis in hematopoietic stem cell transplant recipients.  Med Mycol. 2005;  43 (8) 705-710
  • 11 Masannat F Y, Ampel N M. Coccidioidomycosis in patients with HIV-1 infection in the era of potent antiretroviral therapy.  Clin Infect Dis. 2010;  50 (1) 1-7
  • 12 Rosenstein N E, Emery K W, Werner S B et al.. Risk factors for severe pulmonary and disseminated coccidioidomycosis: Kern County, California, 1995–1996.  Clin Infect Dis. 2001;  32 (5) 708-715
  • 13 Cairns L, Blythe D, Kao A et al.. Outbreak of coccidioidomycosis in Washington state residents returning from Mexico.  Clin Infect Dis. 2000;  30 (1) 61-64
  • 14 Lan F, Tong Y Z, Huang H, Xiong W N, Xu Y J, Xiong S D. Primary pulmonary coccidioidomycosis in China.  Respirology. 2010;  15 (4) 722-725
  • 15 Flynn N M, Hoeprich P D, Kawachi M M et al.. An unusual outbreak of windborne coccidioidomycosis.  N Engl J Med. 1979;  301 (7) 358-361
  • 16 Schneider E, Hajjeh R A, Spiegel R A et al.. A coccidioidomycosis outbreak following the Northridge, Calif, earthquake.  JAMA. 1997;  277 (11) 904-908
  • 17 Park B J, Sigel K, Vaz V et al.. An epidemic of coccidioidomycosis in Arizona associated with climatic changes, 1998–2001.  J Infect Dis. 2005;  191 (11) 1981-1987
  • 18 Fierer JKT, Kirkland T. Questioning CDC’s “select agent” criteria.  Science. 2002;  295 (5552) 43
  • 19 Vugia D J, Cummings K C, Karon A. Centers for Disease Control and Prevention . Increase in coccidioidomycosis-California, 2000–2007.  MMWR Morb Mortal Wkly Rep. 2009;  58 (5) 105-109
  • 20 DiCaudo D J, Yiannias J A, Laman S D, Warschaw K E. The exanthem of acute pulmonary coccidioidomycosis: clinical and histopathologic features of 3 cases and review of the literature.  Arch Dermatol. 2006;  142 (6) 744-746
  • 21 Lonky S A, Catanzaro A, Moser K M, Einstein H. Acute coccidioidal pleural effusion.  Am Rev Respir Dis. 1976;  114 (4) 681-688
  • 22 Mayer A P, Panse P F, Ko M G, Files J A, Ruddy B E, Blair J E. Does the presence of mediastinal adenopathy confer a risk for disseminated infection in non-immunocompromised persons with pulmonary coccidioidomycosis? In: Programs and Abstracts of the 55th Annual Coccidioidomycosis Study Group Davis, CA; 2011. Oral presentation. 
  • 23 Galgiani J N, Ampel N M, Catanzaro A, Johnson R H, Stevens D A, Williams P L. Infectious Diseases Society of America . Practice guideline for the treatment of coccidioidomycosis.  Clin Infect Dis. 2000;  30 (4) 658-661
  • 24 Merchant M, Romero A O, Libke R D, Joseph J. Pleural effusion in hospitalized patients with Coccidioidomycosis.  Respir Med. 2008;  102 (4) 537-540
  • 25 Larsen R A, Jacobson J A, Morris A H, Benowitz B A. Acute respiratory failure caused by primary pulmonary coccidioidomycosis. Two case reports and a review of the literature.  Am Rev Respir Dis. 1985;  131 (5) 797-799
  • 26 Arsura E L, Kilgore W B. Miliary coccidioidomycosis in the immunocompetent.  Chest. 2000;  117 (2) 404-409
  • 27 Ampel N M, Ryan K J, Carry P J, Wieden M A, Schifman R B. Fungemia due to Coccidioides immitis: an analysis of 16 episodes in 15 patients and a review of the literature.  Medicine (Baltimore). 1986;  65 (5) 312-321
  • 28 Rempe S, Sachdev M S, Bhakta R, Pineda-Roman M, Vaz A, Carlson R W. Coccidioides immitis fungemia: clinical features and survival in 33 adult patients.  Heart Lung. 2007;  36 (1) 64-71
  • 29 Arsura E L, Bellinghausen P L, Kilgore W B, Abraham J J, Johnson R H. Septic shock in coccidioidomycosis.  Crit Care Med. 1998;  26 (1) 62-65
  • 30 Lopez A M, Williams P L, Ampel N M. Acute pulmonary coccidioidomycosis mimicking bacterial pneumonia and septic shock: a report of two cases.  Am J Med. 1993;  95 (2) 236-239
  • 31 Tang B M, Craig J C, Eslick G D, Seppelt I, McLean A S. Use of corticosteroids in acute lung injury and acute respiratory distress syndrome: a systematic review and meta-analysis.  Crit Care Med. 2009;  37 (5) 1594-1603
  • 32 Shibli M, Ghassibi J, Hajal R, O’Sullivan M. Adjunctive corticosteroids therapy in acute respiratory distress syndrome owing to disseminated coccidioidomycosis.  Crit Care Med. 2002;  30 (8) 1896-1898
  • 33 Wright P W, Pappagianis D, Wilson M et al.. Donor-related coccidioidomycosis in organ transplant recipients.  Clin Infect Dis. 2003;  37 (9) 1265-1269
  • 34 Tang T H, Tsang O T. Images in clinical medicine: fungal infection from sweeping in the wrong place.  N Engl J Med. 2011;  364 (2) e3
  • 35 De Pauw B, Walsh T J, Donnelly J P European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group et al. Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group.  Clin Infect Dis. 2008;  46 (12) 1813-1821
  • 36 Sandhu G S, Kline B C, Stockman L, Roberts G D. Molecular probes for diagnosis of fungal infections.  J Clin Microbiol. 1995;  33 (11) 2913-2919
  • 37 Huppert M, Peterson E T, Sun S H, Chitjian P A, Derrevere W J. Evaluation of a latex particle agglutination test for coccidioidomycosis.  Am J Clin Pathol. 1968;  49 (1) 96-102
  • 38 Kuberski T, Herrig J, Pappagianis D. False-positive IgM serology in coccidioidomycosis.  J Clin Microbiol. 2010;  48 (6) 2047-2049
  • 39 Pappagianis D, Krasnow R I, Beall S. False-positive reactions of cerebrospinal fluid and diluted sera with the coccidioidal latex-agglutination test.  Am J Clin Pathol. 1976;  66 (5) 916-921
  • 40 Crum N F, Lederman E R, Stafford C M, Parrish J S, Wallace M R. Coccidioidomycosis: a descriptive survey of a reemerging disease. Clinical characteristics and current controversies.  Medicine (Baltimore). 2004;  83 (3) 149-175
  • 41 Durkin M, Connolly P, Kuberski T et al.. Diagnosis of coccidioidomycosis with use of the Coccidioides antigen enzyme immunoassay.  Clin Infect Dis. 2008;  47 (8) e69-e73
  • 42 Johnson S M, Simmons K A, Pappagianis D. Amplification of coccidioidal DNA in clinical specimens by PCR.  J Clin Microbiol. 2004;  42 (5) 1982-1985
  • 43 Vucicevic D, Blair J E, Binnicker M J et al.. The utility of Coccidioides polymerase chain reaction testing in the clinical setting.  Mycopathologia. 2010;  170 (5) 345-351
  • 44 Galgiani J N, Stevens D A, Graybill J R, Dismukes W E, Cloud G A. Ketoconazole therapy of progressive coccidioidomycosis: comparison of 400- and 800-mg doses and observations at higher doses.  Am J Med. 1988;  84 (3 Pt 2) 603-610
  • 45 Graybill J R, Craven P C, Donovan W, Matthew E B. Ketoconazole therapy for systemic fungal infections: inadequacy of standard dosage regimens.  Am Rev Respir Dis. 1982;  126 (1) 171-174
  • 46 Pont A, Graybill J R, Craven P C et al.. High-dose ketoconazole therapy and adrenal and testicular function in humans.  Arch Intern Med. 1984;  144 (11) 2150-2153
  • 47 Galgiani J N, Catanzaro A, Cloud G A Mycoses Study Group et al. Comparison of oral fluconazole and itraconazole for progressive, nonmeningeal coccidioidomycosis: a randomized, double-blind trial.  Ann Intern Med. 2000;  133 (9) 676-686
  • 48 Galgiani J N, Catanzaro A, Cloud G A The NIAID-Mycoses Study Group et al. Fluconazole therapy for coccidioidal meningitis.  Ann Intern Med. 1993;  119 (1) 28-35
  • 49 Johnson R H, Einstein H E. Coccidioidal meningitis.  Clin Infect Dis. 2006;  42 (1) 103-107
  • 50 Graybill J R, Stevens D A, Galgiani J N, Dismukes W E, Cloud G A. NAIAD Mycoses Study Group . Itraconazole treatment of coccidioidomycosis.  Am J Med. 1990;  89 (3) 282-290
  • 51 Barone J A, Moskovitz B L, Guarnieri J et al.. Enhanced bioavailability of itraconazole in hydroxypropyl-beta-cyclodextrin solution versus capsules in healthy volunteers.  Antimicrob Agents Chemother. 1998;  42 (7) 1862-1865
  • 52 Proia L A, Tenorio A R. Successful use of voriconazole for treatment of Coccidioides meningitis.  Antimicrob Agents Chemother. 2004;  48 (6) 2341
  • 53 Freifeld A, Proia L, Andes D et al.. Voriconazole use for endemic fungal infections.  Antimicrob Agents Chemother. 2009;  53 (4) 1648-1651
  • 54 Stevens D A, Rendon A, Gaona-Flores V et al.. Posaconazole therapy for chronic refractory coccidioidomycosis.  Chest. 2007;  132 (3) 952-958
  • 55 Anstead G M, Corcoran G, Lewis J, Berg D, Graybill J R. Refractory coccidioidomycosis treated with posaconazole.  Clin Infect Dis. 2005;  40 (12) 1770-1776
  • 56 Catanzaro A, Cloud G A, Stevens D A et al.. Safety, tolerance, and efficacy of posaconazole therapy in patients with nonmeningeal disseminated or chronic pulmonary coccidioidomycosis.  Clin Infect Dis. 2007;  45 (5) 562-568
  • 57 González G M, Tijerina R, Najvar L K et al.. Correlation between antifungal susceptibilities of Coccidioides immitis in vitro and antifungal treatment with caspofungin in a mouse model.  Antimicrob Agents Chemother. 2001;  45 (6) 1854-1859
  • 58 Park D W, Sohn J W, Cheong H J et al.. Combination therapy of disseminated coccidioidomycosis with caspofungin and fluconazole.  BMC Infect Dis. 2006;  6 26
  • 59 Antony S. Use of the echinocandins (caspofungin) in the treatment of disseminated coccidioidomycosis in a renal transplant recipient.  Clin Infect Dis. 2004;  39 (6) 879-880
  • 60 Clemons K V, Sobel R A, Williams P L, Pappagianis D, Stevens D A. Efficacy of intravenous liposomal amphotericin B (AmBisome) against coccidioidal meningitis in rabbits.  Antimicrob Agents Chemother. 2002;  46 (8) 2420-2426
  • 61 Clemons K V, Capilla J, Sobel R A, Martinez M, Tong A J, Stevens D A. Comparative efficacies of lipid-complexed amphotericin B and liposomal amphotericin B against coccidioidal meningitis in rabbits.  Antimicrob Agents Chemother. 2009;  53 (5) 1858-1862
  • 62 Ampel N M, Kramer L A. In vitro modulation of cytokine production by lymphocytes in human coccidioidomycosis.  Cell Immunol. 2003;  221 (2) 115-121
  • 63 Ampel N M, Christian L. In vitro modulation of proliferation and cytokine production by human peripheral blood mononuclear cells from subjects with various forms of coccidioidomycosis.  Infect Immun. 1997;  65 (11) 4483-4487
  • 64 Vinh D C, Masannat F, Dzioba R B, Galgiani J N, Holland S M. Refractory disseminated coccidioidomycosis and mycobacteriosis in interferon-gamma receptor 1 deficiency.  Clin Infect Dis. 2009;  49 (6) e62-e65
  • 65 Vinh D C. Coccidioidal meningitis: disseminated disease in patients without HIV/AIDS.  Medicine (Baltimore). 2011;  90 (1) 87
  • 66 Kuberski T T, Servi R J, Rubin P J. Successful treatment of a critically ill patient with disseminated coccidioidomycosis, using adjunctive interferon-gamma.  Clin Infect Dis. 2004;  38 (6) 910-912
  • 67 Stevens D A, Clemons K V, Levine H B et al.. Expert opinion: what to do when there is Coccidioides exposure in a laboratory.  Clin Infect Dis. 2009;  49 (6) 919-923
  • 68 Blair J E, Mulligan D C. Coccidioidomycosis in healthy persons evaluated for liver or kidney donation.  Transpl Infect Dis. 2007;  9 (1) 78-82
  • 69 Hector R F, Zimmer B L, Pappagianis D. Evaluation of nikkomycins X and Z in murine models of coccidioidomycosis, histoplasmosis, and blastomycosis.  Antimicrob Agents Chemother. 1990;  34 (4) 587-593

George R. Thompson IIIM.D. 

Department of Internal Medicine, Division of Infectious Diseases, University of California–Davis

1 Shields Ave., Tupper Hall, Rm. 3146, Davis, CA 95616

Email: grthompson@ucdavis.edu

    >